Journal of the American Society of Echocardiography
Volume 21, Issue 1 , Pages 38-42 , January 2008

Prevalence of Unsuspected and Significant Mitral and Aortic Regurgitation

  • Gregory Stefano, MD

      Affiliations

    • Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Keith Fox, RDMS

      Affiliations

    • Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • Mark Schluchter, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Brian D. Hoit, MD

      Affiliations

    • Department of Medicine, University Hospitals Case Medical Center, Cleveland, Ohio
    • Department of Medicine, Cleveland, Ohio, Case Western Reserve University, Cleveland, Ohio.
    • Corresponding Author InformationReprint requests: Brian D. Hoit, MD, Division of Cardiology, Case Western Reserve University, 11100 Euclid Ave, MS 5038, Cleveland, OH 44106-5038.

References 

  1. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 1999;34:1153–1158
  2. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283:1703–1709
  3. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation. 1999;100:2161–2167
  4. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham heart study). Am J Cardiol. 1999;83:897–902
  5. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M, et al. Prevalence and correlates of aortic regurgitation in American Indians: the strong heart study. J Am Coll Cardiol. 2000;36:461–467
  6. Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, et al. Prevalence and correlates of mitral regurgitation in a population-based sample (the strong heart study). Am J Cardiol. 2001;87:298–304
  7. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802
  8. Palmieri V, Wachtell K, Bella JN, Gerdts E, Papademetriou V, Nieminen MS, et al. Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. J Hum Hypertens. 2004;18:423–430
  9. Akasaka T, Yoshikawa J, Yoshida K, Okumachi F, Koizumi K, Shiratori K, et al. Age-related valvular regurgitation: a study by pulsed Doppler echocardiography. Circulation. 1987;76:262–265
  10. Berger M, Hecht SR, Van Tosh A, Lingam U. Pulsed and continuous wave Doppler echocardiographic assessment of valvular regurgitation in normal subjects. J Am Coll Cardiol. 1989;13:1540–1545
  11. Hoit BD, Jones M, Eidbo EE, Elias W, Sahn DJ. Sources of variability for Doppler color flow mapping of regurgitant jets in an animal model of mitral regurgitation. J Am Coll Cardiol. 1989;13:1631–1636
  12. Kontos J, Papademetriou V, Wachtell K, Palmieri V, Liu JE, Gerdts E, et al. Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens. 2004;18:431–436
  13. Gardin JM, Constantine G, Davis K, Leung C, Reid CL. Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens. Echocardiography. 2006;23:569–576
  14. Klein AL, Burstow DJ, Tajik AJ, Zachariah PK, Taliercio CP, Taylor CL, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr. 1990;3:54–63
  15. Palmieri V, Bella JN, Arnett DK, Oberman A, Kitzman DW, Hopkins PN, et al. Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the hypertension genetic epidemiology network study. Am Heart J. 2003;145:1071–1077
  16. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339:713–718
  17. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo: sustained-release dexfenfluramine study group. N Engl J Med. 1998;339:725–732
  18. Paunovic K, Jakovljevic B, Stojanov V. Left ventricular hypertrophy in hypertensive obese women. Acta Cardiol. 2006;61:623–629
  19. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, Pendleton RC, et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension. 2007;49:34–39
  20. Gottdiener JS, Panza JA, St John Sutton M, Bannon P, Kushner H, Weissman NJ. Testing the test: the reliability of echocardiography in the sequential assessment of valvular regurgitation. Am Heart J. 2002;144:115–121

PII: S0894-7317(07)00392-6

doi: 10.1016/j.echo.2007.05.006

Journal of the American Society of Echocardiography
Volume 21, Issue 1 , Pages 38-42 , January 2008

Article Tools